Heart failure & cardiomyopathies
Economic evaluation of the TriageHF Plus clinical pathway for device-based remote monitoring in heart failure
Authors' conclusion
The TriageHF Plus pathway is cost-effective for the remote monitoring of HF in patients with CIEDs.
Study context
- Population
- Patients with heart failure (HF) and a compatible cardiac implantable electronic device (CIED), public hospital settingsparticipants in the TriageHF Plus multicentre study, model based on a site of 300 eligible patients
- Participants
- 758 patients
- Comparison
- TriageHF Plus versus usual care
- Outcome
- Hospitalisations prevented (site size of 300)
- Follow-up
- 5 years
Methodological detailseconomic model, lifetime horizon, individual patient-level data, costs and benefits discounted at 3.5% per annum
- Economic model
- Lifetime horizon
- Individual patient-level data
- Costs and benefits discounted at 3.5% per annum
Main finding
As reported in the abstract
Hospitalisations prevented by TriageHF Plus
384
363–405
Further findings
| Outcome | Cost saving (per person-lifetime) (CI) |
|---|---|
| Cost saving per person-lifetimeSaved with TriageHF Plus · Results were robust to changes in key input parameters. | £3989 (£1812-£5563) |
- Cost saving per person-lifetime — More effective and cost-saving in simulations
- 99.4%
Number needed to avoid one hospitalisation · lifetime
- People needing lifetime access to TriageHF Plus to avoid one hospitalisation
- 1.7
Original publication
Economic evaluation of the TriageHF Plus clinical pathway for device-based remote monitoring in heart failure. Heart. Published 17 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →